Next-generation genetic medicines require differentiated antibodies that serve as both therapeutics and targeted delivery vehicles. Alloy Therapeutics enables this through an integrated, AI-driven discovery platform that accelerates progression from immune repertoire to optimised candidate. By combining AI/ML-guided selection, in silico optimisation, and predictive developability modeling, we survey billions of sequences to prioritise diverse, high-affinity, manufacturable leads from transgenic mice, human VHH libraries, or partner-derived parentals— validated via high-throughput functional screening. We highlight early data from antibody–oligonucleotide conjugates using transferrin receptor-binding antibodies to deliver genetic payloads, achieving potent knockdown and demonstrating precise delivery to challenging tissues.
Davide Schiavone, Head of GEO Core, Alloy Therapeutics
